The effects of 5-fluorouracil on prostatic DNA synthesis

Investigative Urology
|September 1, 1975
PubMed

Insights

A new rat prostate cancer model studies nonhormonal drugs. 5-fluorouracil significantly reduced prostate DNA synthesis but showed no antiandrogenic effects, indicating its potential for targeted cancer therapy.

Area of Science:

  • Oncology
  • Pharmacology
  • Urology

Background:

  • Prostate cancer growth is androgen-dependent.
  • Hormonal therapies are standard, but nonhormonal drugs offer alternative strategies.
  • A suitable animal model is crucial for evaluating novel therapeutic agents.

Purpose of the Study:

  • To develop and validate a new animal model for studying nonhormonal drug effects on prostate growth.
  • To investigate the efficacy of the antimetabolite 5-fluorouracil in this model.
  • To assess the drug's mechanism of action and potential antiandrogenic activity.

Main Methods:

  • Development of an androgen-stimulated castrate rat model.
  • Administration of 5-fluorouracil to assess its impact on prostatic DNA synthesis.
  • Evaluation of prostate size and antiandrogenic activity in normal intact rats.
  • Analysis of drug distribution within prostatic tissue homogenates.

Main Results:

  • 5-fluorouracil reduced prostatic DNA synthesis by 60% in androgen-stimulated castrate rats.
  • The drug did not significantly alter prostate size in normal intact animals.
  • No significant antiandrogenic activity was observed for 5-fluorouracil.
  • The drug primarily distributed to the acid-soluble fraction of prostatic homogenate.

Conclusions:

  • The developed rat model is effective for studying nonhormonal drug effects on prostate growth.
  • 5-fluorouracil demonstrates potential as a nonhormonal agent by inhibiting prostatic DNA synthesis.
  • The drug's mechanism appears independent of direct antiandrogenic activity.

Related Concept Videos

Mutations01:35

Mutations

Mutations are changes in the sequence of DNA. These changes can occur spontaneously or they can be induced by exposure to environmental factors. Mutations can be characterized in a number of different ways: whether and how they alter the amino acid sequence of the protein, whether they occur over a small or large area of DNA, and whether they occur in somatic cells or germline cells.
Chromosomal Alterations Are Large-Scale Mutations
While point mutations are changes in a single nucleotide in...
Pharmacogenetics of Drug Targets: β₂-Adrenergic Receptors, Apo E, Thymidylate Synthase01:11

Pharmacogenetics of Drug Targets: β₂-Adrenergic Receptors, Apo E, Thymidylate Synthase

Genetic polymorphisms in drug targets have emerged as critical determinants of interindividual variability in drug response and toxicity. Pharmacogenomic investigations increasingly focus on identifying these variations to personalize and optimize therapeutic interventions. A drug target may be a receptor, enzyme, or signaling protein involved in pharmacologic responses or disease-related pathways. While early pharmacogenetic studies focused primarily on drug metabolism, current research...
Inhibitors of Bacterial DNA Synthesis01:28

Inhibitors of Bacterial DNA Synthesis

Bacterial pathogens depend on precise and efficient DNA replication to sustain infection. Two type II topoisomerases—DNA gyrase and topoisomerase IV—are critical to this process, as they resolve DNA supercoiling and unlink chromosomes during replication. Fluoroquinolones, synthetic derivatives of quinolones, exploit this mechanism by stabilizing the transient DNA–enzyme cleavage complex, preventing strand religation, and causing lethal double-strand breaks. These antibiotics are selectively...